newsfilter
← Latest News
Business Wire·

Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

Clinical Trial Site Activations in the United States Expected to Begin Q4 2026 Summit Therapeutics Inc. (NASDAQ:SMMT) today announced a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group